Mainz Biomed Net Worth
Mainz Biomed Net Worth Breakdown | MYNZ |
Mainz Biomed Net Worth Analysis
Mainz Biomed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mainz Biomed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mainz Biomed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mainz Biomed's net worth analysis. One common approach is to calculate Mainz Biomed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mainz Biomed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mainz Biomed's net worth. This approach calculates the present value of Mainz Biomed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mainz Biomed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mainz Biomed's net worth. This involves comparing Mainz Biomed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mainz Biomed's net worth relative to its peers.
Enterprise Value |
|
To determine if Mainz Biomed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mainz Biomed's net worth research are outlined below:
| Mainz Biomed BV is way too risky over 90 days horizon | |
| Mainz Biomed BV appears to be risky and price may revert if volatility continues | |
| Mainz Biomed BV has high likelihood to experience some financial distress in the next 2 years | |
| Mainz Biomed BVhas 3,566,004 shares shorted by Mainz Biomed investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 177.62 K. | |
| Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Mainz Biomed BV has a frail financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific |
Mainz Biomed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mainz Biomed BV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mainz Biomed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of April 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Mainz Biomed's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.96 M.Market Cap |
|
Project Mainz Biomed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.32) | (4.10) | |
| Return On Assets | (1.71) | (1.79) | |
| Return On Equity | (8.09) | (7.69) |
When accessing Mainz Biomed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mainz Biomed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mainz Biomed's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Mainz Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mainz Biomed BV. Check Mainz Biomed's Beneish M Score to see the likelihood of Mainz Biomed's management manipulating its earnings.
Evaluate Mainz Biomed's management efficiency
Mainz Biomed BV has return on total asset (ROA) of (0.9924) % which means that it has lost $0.9924 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (43.3371) %, meaning that it created substantial loss on money invested by shareholders. Mainz Biomed's management efficiency ratios could be used to measure how well Mainz Biomed manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.3 in 2024. Return On Capital Employed is likely to rise to -4.1 in 2024. At this time, Mainz Biomed's Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 7.7 M in 2024, whereas Total Assets are likely to drop slightly above 10.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.20 | 0.22 | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | 5.80 | 6.09 | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | 5.80 | 6.09 | |
| Enterprise Value | 19.2 M | 18.2 M |
Leadership effectiveness at Mainz Biomed BV is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 23.1696 | Revenue 917.2 K | Quarterly Revenue Growth 0.046 | Revenue Per Share 0.046 | Return On Equity (43.34) |
Mainz Biomed Corporate Filings
6K | 29th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
13A | 7th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 10th of May 2024 Other Reports | ViewVerify |
Mainz Biomed Earnings per Share Projection vs Actual
Mainz Biomed Corporate Management
| Corinna Gorges | Head RD | Profile | |
| Chris PMP | Chief Officer | Profile | |
| Frank KriegSchneider | Chief Officer | Profile | |
| Darin Leigh | Chief Officer | Profile | |
| Philipp Freese | Chief Officer | Profile | |
| Petra Ploesser | Head Quality | Profile | |
| Guido Baechler | CEO Director | Profile |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.